Cat. #154820
Anti-CD9 [P1/33/2] rAb
Cat. #: 154820
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: CD9
Class: Recombinant
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Absolute Antibody; University of Oxford
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-CD9 [P1/33/2] rAb
- Alternate name: CD9 Molecule; Cell Growth-Inhibiting Gene 2 Protein; Motility Related Protein-1; Leukocyte Antigen MIC3; CD9 Antigen (P24); Tetraspanin-29; 5H9 Antigen; TSPAN29; MRP-1
- Clone: P1/33/2
- Tool sub type: Primary antibody
- Class: Recombinant
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Description: CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FcgRIIa. It may play a role in cell migration.Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for functional studies on platelets
- Immunogen: Acute lymphoblastic leukaemia cells
- Isotype: IgG1
Target Details
- Target: CD9
- Target background: CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FcgRIIa. It may play a role in cell migration.Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for Fn studies on platelets
Handling
- Format: Liquid
- Unit size: 100 ug
- Shipping conditions: Shipping at 4° C
References
- CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells.
- Jennings et al. 1993. CD9 cluster workshop report: cell surface binding and Fn analysis. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 2, Oxford University Press, Oxford, New York and Tokyo, p 1249-51
- Taghizadeh et al. 2010. PLoS One. 5(12):e15183. PMID: 21203549.
